In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.


This content is currently on FREE ACCESS, enjoy another 48 days of free consultation

 

Assessment of the risk of decrease of the quality of life in patients with stable coronary artery disease complicated by chronic heart failure

Session Poster Session 3

Speaker Associate Professor Valentyn Maslovskyi

Congress : EuroPrevent 2019

  • Topic : heart failure
  • Sub-topic : Chronic Heart Failure - Other
  • Session type : Poster Session
  • FP Number : P695

Authors : VP Ivanov (Vinnitsa,UA), YU Savitska (Vinnitsa,UA), VI Maslovskyi (Vinnitsa,UA), IA Mezhiievska (Vinnitsa,UA), LV Burdeina (Vinnitsa,UA), LA Vozniuk (Vinnitsa,UA), II Leta (Vinnitsa,UA), YV Maslovskyi (Vinnitsa,UA)

15 views

Authors:
VP Ivanov1 , YU Savitska1 , VI Maslovskyi1 , IA Mezhiievska1 , LV Burdeina1 , LA Vozniuk1 , II Leta1 , YV Maslovskyi1 , 1National Pirogov Memorial Medical University, Internal medicine #3 - Vinnitsa - Ukraine ,

Citation:

Introduction: Coronary artery disease (CAD) is one of the main causes of high mortality and disability of the population in many industrialized countries, which is a serious a medical, social and economic problem. Purpose : to verify the clinical and instrumental indices associated with a decrease of life quality in patients with stable coronary artery disease complicated by chronic heart failure. Materials and methods: To analyze received data there was used a statistical matrix that included 113 patients with stable coronary artery disease (?AD) complicated by chronic heart failure (CHF) stage C for ACCF/ANA II and III functional class (FC) by NYHA. The average age of patients was 60.0 ± 0.74 years old. All studies conform to the principles of the Declaration of Helsinki of the World Medical Association. Inclusion criteria for participation in the study were: 1) the presence of stable CAD, complicated by CHF II and III NYHA FC; 2) age =75 years old. Exclusion criteria: 1) CAD without CHF or with CHF I or IV NYHA FC; 2) age ?75 years; 3) moved myocardial infarction or stroke within the last 3 months; 5) severe comorbid conditions; 6) severe violations of heart rhythm and conduction. All patients were provided with a comprehensive clinical examination, which included assessment of anamnestic data, physical examination, evaluation of instrumental and laboratory indexes (a total of 87 parameters). Life Quality (LQ) indicators were evaluated by survey using MLHFQ. Identification of risk factors for the reduction of LQ in patients with stable CAD, complicated by CHF was performed using nonparametric correlation analysis of Kendall and multiple linear step-by-step regression between the parameters of LQ (initial parameters of the analysis) and various clinical and instrumental indices. Results: Among the analyzed clinical, laboratory and instrumental options in patients with stable CAD, complicated by CHF, the risk of LQ reduction was most associated with the level of Nt-proBNP =2.414 pg/ml (odds ratio (?R) =8.6), the index of left ventricular mass =190 g/m2 (OR=4.2), the duration of ischemic history =12 years (OR=3.0), the presence of a permanent form of atrial fibrillation (OR=2.9). 
Conclusions: The greatest importance in predicting the risk of decrease of life quality in patients with coronary artery disease, complicated by chronic heart failure stage C by ACCF/ANA II and III functional class by NYHA has Nt-proBNP level, to a lesser extent ? the left ventricular myocardial mass index, the duration of ischemic anamnesis and the presence of a permanent form of atrial fibrillation.

This content is currently on FREE ACCESS, enjoy another 48 days of free consultation

 



Based on your interests

Three reasons why you should become a member

Become a member now
  • 1Access your congress resources all year-round on the New ESC 365
  • 2Get a discount on your next congress registration
  • 3Continue your professional development with free access to educational tools
Become a member now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim, Bristol-Myers Squibb and Pfizer Alliance, and Novartis Pharma AG. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are